AKT1 and metabolic dysfunction-associated steatotic liver disease: Chlorogenic acid is reported to enhance the sensitivity of human hepatocellular carcinoma cells lines to regorafenib treatment by inhibiting PI3K/Akt/mTOR signaling [52] and lessening liver injury by inhibiting autophagy in a rat model of NAFLD [53].